Currently set to Index
Currently set to Follow
PROFILE
search
ask age2b
CART

Improved postprandial glucose control with ultra-rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO-Pump-2

By AGE2B team
November 7, 2021
0
0

Main idea: URLi was efficacious, providing superior PPG control and less time in hypoglycemia but with more frequent infusion-site reactions compared with lispro when administered by CSII.

Abstract

The aim of the study was to evaluate the efficacy and safety of ultra-rapid lispro (URLi) versus lispro (Humalog®) in people with type 1 diabetes on continuous subcutaneous insulin infusion (CSII).

This was a phase 3 16-week treat-to-target study in patients randomized to double-blind URLi (N = 215) or lispro (N = 217). The primary endpoint was the change from baseline Hemoglobin A1c(HbA1c)e A1c(HbA1c) (non-inferiority margin 4.4 mmol/mol [0.4%]), with multiplicity-adjusted objectives for postprandial glucose (PPG) levels during a meal test, and time spent in the target range 70-180 mg/dL (TIR).

Results: URLi was non-inferior to lispro for change in Hemoglobin A1c(HbA1c)e A1c(HbA1c), with a least-squares mean (LSM) difference of 0.3 mmol/mol or 0.02%. URLi was superior to lispro in controlling 1- and 2-h PPG levels after the meal test: LSM difference -1.34 mmol/L (95% CI -2.00, -0.68) or -24.1 mg/dL  at 1 h and -1.54 mmol/L or -27.8 mg/dL (95% CI -42.6, -13.0) at 2 h; both p < .001. TIR and time in hyperglycemia were similar between groups but URLi resulted in significantly less time in hypoglycemia (<3.0 mmol/L [54 mg/dL]) over the daytime, night-time and 24-h period: LSM difference -0.41%, -0.97% and -0.52%, respectively, all p < .05. The incidence of treatment-emergent adverse events was higher with URLi (60.5% vs. 44.7%), driven by infusion-site reaction and infusion-site pain, which was mostly mild or moderate. Rates of severe hypoglycemia and diabetic ketoacidosis were similar between groups.

Source DOM

Leave a Reply

Ask your question

We read all your emails and your text. Your question will be responded by our specialists, or one of the doctors we're working with, or our community

Please complete the required fields.